1. >
  2. News & Events
  3. >
  4. Press Releases

Press Releases

Found 313 Results
Page 1 of 32

Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures


Paris (France), May 16, 2023 – 06:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]

05/16/2023


Publication of the 2022 Annual Financial Report


Paris (France), April 28, 2023 – 9.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the […]

04/28/2023


Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates


Phase 1b/2 trial of AsiDNATM in combination with olaparib in the United States in recurrent ovarian, breast and metastatic castration-resistant […]

04/24/2023


Onxeo will publish its full-year results on April 24, 2023


Paris (France), April 21, 2023 – 8:30 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]

04/21/2023


Onxeo will publish its full-year results on April 21, 2023


Paris (France), April 14, 2023 – 5:35 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]

04/14/2023


Onxeo will publish its full-year results on April 14, 2023


The annual general meeting will be held on June 6, 2023   Paris (France), March 14, 2023 – 6:00 pm […]

03/14/2023


Onxeo: report on the Extraordinary General Meeting of February 6, 2023


Paris (France), February 6, 2023 – 7:30 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]

02/06/2023


Onxeo Announces its Financial Agenda for 2023


Paris (France), January 27, 2023 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]

01/27/2023


ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM


Phase 1b/2 trial of AsiDNATM in combination with olaparib initiated in the United States in recurrent ovarian, breast and metastatic […]

01/25/2023


Onxeo advances its second lead candidate OX425 for the treatment of solid tumors


OX425 is a novel DDR Decoy Agonist which also mediates multiple immunostimulatory effects, making it a promising candidate for combination […]

11/30/2022


Page 1 of 32